Mechanism of glycosaminoglycan-mediated bone and joint disease - Implications for the mucopolysaccharidoses and other connective tissue diseases

被引:175
作者
Simonaro, Calogera M. [1 ]
D'Angelo, Marina [3 ]
He, Xingxuan [1 ]
Eliyahu, Efrat [1 ]
Shtraizent, Nataly [1 ]
Haskins, Mark E. [4 ]
Schuchman, Edward H. [1 ,2 ]
机构
[1] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA
[3] Philadelphia Coll Osteopath Med, Ctr Chron Disorders Aging, Philadelphia, PA USA
[4] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA
关键词
D O I
10.2353/ajpath.2008.070564
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We have previously shown that glycosaminoglycan (GAG) storage in animal models of the mucopolysaccharidoses (NIPS) leads to inflammation and apoptosis within cartilage. We have now extended these findings to synovial tissue and further explored the mechanism underlying GAG-mediated disease. Analysis of NIPS rats, cats, and/or dogs revealed that NIPS synovial fibroblasts and fluid displayed elevated expression of numerous inflammatory molecules, including several proteins important for lipopolysaccharide signaling (eg, Toll-like receptor 4 and lipoprotein binding protein). The expression of tumor necrosis factor, in particular, was elevated up to 50-fold, leading to up-regulation of the osteoclast survival factor, receptor activator of nuclear factor-kappa B ligand, and the appearance of multinucleated osteoclast-like cells in the NIPS bone marrow. Treatment of normal synovial fibroblasts with GAGS also led to production of the prosurvival lipid sphingosine-l-phosphate, resulting in enhanced cell proliferation, consistent with the hyperplastic synovial tissue observed in MPS patients. In contrast, GAG treatment of normal chondrocytes led to production of the proapoptotic lipid ceramide, confirming the enhanced cell death we had previously observed in MPS cartilage. These findings have important implications for the pathogenesis and treatment of MPS and have further defined the mechanism of GAG-stimulated disease.
引用
收藏
页码:112 / 122
页数:11
相关论文
共 45 条
[1]  
Ainola MM, 2005, CLIN EXP RHEUMATOL, V23, P644
[2]   Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: Enzyme dose and interval [J].
Auclair, D ;
Hein, LK ;
Hopwood, JJ ;
Byers, S .
PEDIATRIC RESEARCH, 2006, 59 (04) :538-543
[3]   ARYLSULFATASE B DEFICIENCY IN MAROTEAUX-LAMY SYNDROME - CELLULAR STUDIES AND CARRIER IDENTIFICATION [J].
BERATIS, NG ;
TURNER, BM ;
WEISS, R ;
HIRSCHHORN, K .
PEDIATRIC RESEARCH, 1975, 9 (05) :475-480
[4]   Matrix metalloproteinases: Role in arthritis [J].
Burrage, PS ;
Mix, KS ;
Brinckerhoff, CE .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :529-543
[5]  
Chen QQ, 2006, J RHEUMATOL, V33, P1061
[6]   Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-β1 in synovial fibroblasts from rheumatoid arthritis and normal individuals [J].
Cheon, H ;
Yu, SJ ;
Yoo, DH ;
Chae, IJ ;
Song, GG ;
Sohn, J .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 127 (03) :547-552
[7]   Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy [J].
Cox-Brinkman, J. ;
Smeulders, M. J. C. ;
Hollak, C. E. M. ;
Wijburg, F. A. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (01) :47-50
[8]  
Cuschieri Joseph, 2007, Surg Infect (Larchmt), V8, P91, DOI 10.1089/sur.2006.050
[9]   Phosphatidylcholine-specific phospholipase C (PC-PLC) is required for LPS-mediated macrophage activation through CD14 [J].
Cuschieri, Joseph ;
Billgren, Jens ;
Maier, Ronald V. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 80 (02) :407-414
[10]  
DEVRIESBOUWSTRA JK, 2007, ANN RHEUM DIS 0112